Relevant Contents
Need Tailored Business Continuity Insights?
Contact Us Now for Personalized Guidance!
MHA Consulting has been engaged by a global biopharmaceutical biopharmaceutical company focused on delivering life-transforming therapies for people with rare diseases. The initiative is designed to elevate the sophistication and maturity of the company’s enterprise Business Continuity Management (BCM) program, with a focus on ensuring resilience across its global R&D operations.
The multi-phase project will include orientation sessions, a business impact analysis (BIA), the development of business continuity plans (BCPs) with each business unit for specific loss scenarios, and a full-scale mock disaster exercise. Together, these steps will help safeguard critical research functions, ensure continuity across the R&D value chain, and align recovery strategies with enterprise-wide priorities.
Michael Herrera, CEO of MHA Consulting, noted: “This engagement is about protecting the essential work that drives innovation and patient impact. Mapping critical processes, building practical continuity plans, and validating them through real-world scenarios is a universal priority for any organization that depends on research to advance science, serve patients, or stay competitive.”
Through this collaboration, MHA Consulting will work closely with business leaders across the organization’s therapy areas to identify key dependencies, strengthen preparedness, and embed continuity practices into day-to-day operations. The result will be a stronger, more adaptive R&D function that can continue to deliver outcomes without interruption, even during times of uncertainty.
